Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone978-206-8220
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.67 million
Profitability
Miscellaneous
Employees250
Next Earnings Date10/22/2019 (Estimated)
OptionableNot Optionable
Psychemedics (NASDAQ:PMD) Frequently Asked Questions
What is Psychemedics' stock symbol?
Psychemedics trades on the NASDAQ under the ticker symbol "PMD."
How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?
Psychemedics declared a quarterly dividend on Tuesday, July 23rd. Investors of record on Tuesday, August 6th will be given a dividend of $0.18 per share on Friday, August 16th. This represents a $0.72 dividend on an annualized basis and a dividend yield of 7.73%. The ex-dividend date is Monday, August 5th. View Psychemedics' Dividend History.
How were Psychemedics' earnings last quarter?
Psychemedics Corp. (NASDAQ:PMD) posted its quarterly earnings results on Tuesday, July, 23rd. The company reported $0.14 earnings per share for the quarter. The firm had revenue of $9.29 million for the quarter. Psychemedics had a net margin of 8.86% and a return on equity of 19.14%. View Psychemedics' Earnings History.
When is Psychemedics' next earnings date?
Has Psychemedics been receiving favorable news coverage?
News stories about PMD stock have been trending very negative this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Psychemedics earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Psychemedics.
Are investors shorting Psychemedics?
Psychemedics saw a drop in short interest during the month of September. As of September 30th, there was short interest totalling 11,100 shares, a drop of 32.3% from the August 30th total of 16,400 shares. Based on an average trading volume of 22,400 shares, the short-interest ratio is currently 0.5 days. Currently, 0.2% of the shares of the company are short sold. View Psychemedics' Current Options Chain.
Who are some of Psychemedics' key competitors?
Some companies that are related to Psychemedics include Fulgent Genetics (FLGT), Celcuity (CELC), Enzo Biochem (ENZ), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), Avant Diagnostics (AVDX), CBA Florida (CBAI), Cancer Genetics (CGIX), First Choice Healthcare Solutions (FCHS), OpGen (OPGN) and Aeon Global Health (AGHC).
What other stocks do shareholders of Psychemedics own?
Who are Psychemedics' key executives?
Psychemedics' management team includes the folowing people:
- Mr. Raymond C. Kubacki Jr., Chairman, CEO & Pres (Age 74)
- Mr. Neil Lerner, VP of Fin. & Treasurer (Age 51)
- Dr. Michael I. Schaffer, VP of Laboratory Operations (Age 74)
- Dr. Werner A. Baumgartner Ph.D., Founder
- Ms. Annette Baumgartner, Founder
Who are Psychemedics' major shareholders?
Psychemedics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include North Star Investment Management Corp. (1.45%). Company insiders that own Psychemedics stock include Charles M Doucot, Michael I Schaffer, Neil Lerner and Raymond C Kubacki Jr. View Institutional Ownership Trends for Psychemedics.
Which institutional investors are selling Psychemedics stock?
PMD stock was sold by a variety of institutional investors in the last quarter, including North Star Investment Management Corp.. Company insiders that have sold Psychemedics company stock in the last year include Michael I Schaffer and Neil Lerner. View Insider Buying and Selling for Psychemedics.
How do I buy shares of Psychemedics?
Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Psychemedics' stock price today?
One share of PMD stock can currently be purchased for approximately $9.32.
How big of a company is Psychemedics?
What is Psychemedics' official website?
How can I contact Psychemedics?
Psychemedics' mailing address is 289 GREAT ROAD, ACTON MA, 01720. The company can be reached via phone at 978-206-8220.
MarketBeat Community Rating for Psychemedics (NASDAQ PMD)
MarketBeat's community ratings are surveys of what our community members think about Psychemedics and other stocks. Vote "Outperform" if you believe PMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
